Kendal Chidwick
Datos Biográficos
| ID | 7447170 |
|---|---|
| NOMBRE | Kendal Chidwick |
| NOMBRES | Kendal |
| APELLIDO | Chidwick |
| FIRMA | CHIDWICK K |
| AFILIACIONES | UNSW Sydney |
| ORCID | 0000-0003-4901-4182 |
| VERIFICADO | Sí |
| TOTAL DE OBRAS | 3 |
| TOTAL DE CITAS | 0 |
| TOTAL COMO AUTOR | 3 |
| TOTAL COMO EDITOR | 0 |
| PRIMER AÑO DE PUBLICACIÓN | 2024 |
| AÑO MÁS RECIENTE DE PUBLICACIÓN | 2026 |
| ÍNDICE H | 0 |
Impact of antiretroviral shortages in HIV therapy and prevention uptake in Australia
Human immunodeficiency virus (HIV) remains a major public health priority in Australia, with treatment and prevention efforts underpinned by access to government-subsidised antiretroviral therapy (ART) through the Pharmaceutical Benefits Scheme (PBS). In 2023-2024, multiple tenofovir with emtricitabine products used for HIV treatment and pre-exposure prophylaxis (PrEP) were subject to national shortages, raising concerns about access and continui…
Trends in prescription opioid analgesic use in Australia from 2015 to 2022
Prescribed opioid analgesic use declined between 2015 and 2022 because of reductions in PBS dispensing claims. A quarter of the reduction in PBS dispensing claims was offset by use outside the PBS. Our findings indicate a significant increase in private use, reasons for which may include accessing opioids not PBS-subsidised and circumventing PBS restrictions for PBS-subsidised opioids. Comparing multiple data sources provides a comprehensive acco…
Trends in use of medicines for opioid agonist treatment in Australia, 2013–2022
Patterns of OAT have shifted over the last 10-years with buprenorphine (SL/LAI) now the most common OAT used in Australia. The introduction of LAI buprenorphine has expanded OAT access, particularly in non-community pharmacy settings, and in remote areas
Sin obras prominentes en esta página.
Trends in use of medicines for opioid agonist treatment in Australia, 2013–2022
Patterns of OAT have shifted over the last 10-years with buprenorphine (SL/LAI) now the most common OAT used in Australia. The introduction of LAI buprenorphine has expanded OAT access, particularly in non-community pharmacy settings, and in remote areas
Trends in prescription opioid analgesic use in Australia from 2015 to 2022
Prescribed opioid analgesic use declined between 2015 and 2022 because of reductions in PBS dispensing claims. A quarter of the reduction in PBS dispensing claims was offset by use outside the PBS. Our findings indicate a significant increase in private use, reasons for which may include accessing opioids not PBS-subsidised and circumventing PBS restrictions for PBS-subsidised opioids. Comparing multiple data sources provides a comprehensive acco…
Impact of antiretroviral shortages in HIV therapy and prevention uptake in Australia
Human immunodeficiency virus (HIV) remains a major public health priority in Australia, with treatment and prevention efforts underpinned by access to government-subsidised antiretroviral therapy (ART) through the Pharmaceutical Benefits Scheme (PBS). In 2023-2024, multiple tenofovir with emtricitabine products used for HIV treatment and pre-exposure prophylaxis (PrEP) were subject to national shortages, raising concerns about access and continui…
Internal Medicine (2 obras) · Medicine (2 obras) · Opioid (2 obras) · Opioid Use Disorder Treatment (2 obras) · Analgesic (1 obras) · Anesthesia (1 obras) · Anesthesia and Pain Management (1 obras) · Antiretroviral therapy (1 obras) · Buprenorphine (1 obras) · Economic shortage (1 obras)